[go: up one dir, main page]

BR9607310A - Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante - Google Patents

Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante

Info

Publication number
BR9607310A
BR9607310A BR9607310A BR9607310A BR9607310A BR 9607310 A BR9607310 A BR 9607310A BR 9607310 A BR9607310 A BR 9607310A BR 9607310 A BR9607310 A BR 9607310A BR 9607310 A BR9607310 A BR 9607310A
Authority
BR
Brazil
Prior art keywords
agent
immunisuppressive
recombinant adenovirus
combining drugs
vivo
Prior art date
Application number
BR9607310A
Other languages
English (en)
Inventor
Jean-Francois Bach
Lucienne Chatenoud
Hedi Haddada
Michelle Webb
Michel Perricaudet
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa
Publication of BR9607310A publication Critical patent/BR9607310A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9607310A 1995-02-14 1996-02-12 Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante BR9607310A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9501662A FR2730411B1 (fr) 1995-02-14 1995-02-14 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
PCT/FR1996/000218 WO1996025177A1 (fr) 1995-02-14 1996-02-12 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (1)

Publication Number Publication Date
BR9607310A true BR9607310A (pt) 1997-11-25

Family

ID=9476106

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607310A BR9607310A (pt) 1995-02-14 1996-02-12 Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante

Country Status (23)

Country Link
US (2) US20030004091A1 (pt)
EP (1) EP0809516B1 (pt)
JP (1) JPH11500430A (pt)
KR (1) KR100402540B1 (pt)
AT (1) ATE204481T1 (pt)
AU (1) AU717218B2 (pt)
BR (1) BR9607310A (pt)
CA (1) CA2211039C (pt)
CZ (1) CZ258197A3 (pt)
DE (1) DE69614668T2 (pt)
DK (1) DK0809516T3 (pt)
ES (1) ES2163612T3 (pt)
FI (1) FI119176B (pt)
FR (1) FR2730411B1 (pt)
GR (1) GR3036438T3 (pt)
HU (1) HU222991B1 (pt)
IL (1) IL117116A0 (pt)
MX (1) MX9706017A (pt)
NO (1) NO320072B1 (pt)
PT (1) PT809516E (pt)
SK (1) SK282235B6 (pt)
WO (1) WO1996025177A1 (pt)
ZA (1) ZA961161B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
EP0942747A1 (en) * 1996-08-26 1999-09-22 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
AU1288099A (en) 1997-10-30 1999-05-24 Cornell Research Foundation Inc. A method of inhibiting an immune response to a recombinant vector
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU5470900A (en) * 1999-06-08 2000-12-28 Children's Hospital Of Philadelphia, The Methods for preventing formation of inhibitory antibodies in the setting of genetherapy
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AU2001259691B2 (en) 2000-05-12 2006-02-16 Genzyme Corporation Modulators of TNF-alpha signaling
JP5033303B2 (ja) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
CA2461905A1 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
ATE520400T1 (de) * 2002-11-21 2011-09-15 Genzyme Corp Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗cd3及び抗原特異的免疫療法
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
AU5965294A (en) * 1993-01-08 1994-08-15 Exemplar Corporation An (in vitro)/(in vivo) method for identifying anti-neoplastic drugs
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus

Also Published As

Publication number Publication date
HUP9800635A2 (hu) 1998-07-28
FI973323A0 (fi) 1997-08-13
EP0809516B1 (fr) 2001-08-22
SK110897A3 (en) 1998-01-14
FR2730411A1 (fr) 1996-08-14
HUP9800635A3 (en) 2000-12-28
CZ258197A3 (en) 1997-11-12
DE69614668D1 (de) 2001-09-27
AU4723896A (en) 1996-09-04
DE69614668T2 (de) 2002-06-27
US20040265276A1 (en) 2004-12-30
AU717218B2 (en) 2000-03-23
FR2730411B1 (fr) 1997-03-28
SK282235B6 (sk) 2001-12-03
KR19980702199A (ko) 1998-07-15
MX9706017A (es) 1997-11-29
CA2211039A1 (fr) 1996-08-22
GR3036438T3 (en) 2001-11-30
FI973323L (fi) 1997-08-13
PT809516E (pt) 2002-02-28
KR100402540B1 (ko) 2004-05-07
ZA961161B (en) 1996-08-07
US20030004091A1 (en) 2003-01-02
NO973724L (no) 1997-08-13
IL117116A0 (en) 1996-06-18
NO973724D0 (no) 1997-08-13
FI119176B (fi) 2008-08-29
ES2163612T3 (es) 2002-02-01
WO1996025177A1 (fr) 1996-08-22
HU222991B1 (hu) 2004-01-28
NO320072B1 (no) 2005-10-17
JPH11500430A (ja) 1999-01-12
DK0809516T3 (da) 2001-12-17
EP0809516A1 (fr) 1997-12-03
CA2211039C (fr) 2011-12-06
ATE204481T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
BR9607310A (pt) Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
HK1026378A1 (en) Syringe serving also as an ampoule and syringe forcollecting blood.
BR9609176A (pt) Composi-{es de agente biolÄgico
MX9706109A (es) Moleculas de adn, preparacion y utilizacion en terapia genica.
SG65061A1 (en) Drug delivery system for two or more active substances
GR3032744T3 (en) Surface expression of enzyme in gene directed prodrug therapy
BR9804500B1 (pt) derivado de amida, referida composição farmacêutica e agente terapêutico.
ES2130428T3 (es) Cristales de insulina asp-b28.
AU2832297A (en) Morphogen treatment for chronic renal failure
WO2000030622A3 (de) Verwendung von dialkylfumaraten zur behandlung von host-versus-graft reaktionen und von autoimmunerkrankungen
PL317105A1 (en) Compositions containing dna and p53 damaging agents
NZ335799A (en) Improvements in or relating to diagnostic/therapeutic agents
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
AU2001258638A1 (en) Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
AU3651595A (en) Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases
IL128768A0 (en) Transdermal therapeutic system containing oestriol
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.
ITRM940545A0 (it) Preparato ad uso cosmetico e/o farmaceutico, con carbone attivo e sostanze disperdenti.
UA30011A (uk) Спосіб профілактики гострих стресових уражень шлунково-кишкового тракту після порожнинних оперативних втручань

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART 36 DA LPI (LEI 9.279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.